Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

VP Controller, PAO

COO & GC

EVP, CBO & Head of Merus US

President, CEO & PFO

EVP, GC and Head of Utrecht

SVP & Chief Technology Officer

SVP, Chief Development Officer

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-12-19	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2023-12-15	Premium	acquired	Premium	Premium	Premium	COO & GC
2023-12-15	Premium	sold	Premium	Premium	Premium	COO & GC
2023-12-08	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2023-12-01	Premium	acquired	Premium	Premium	Premium	VP Controller, PAO
2023-12-01	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2023-06-01	Premium	acquired	Premium	Premium	Premium	VP Controller, PAO
2023-06-01	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2023-04-14	Premium	acquired	Premium	Premium	Premium	-
2023-04-06	Premium	acquired	Premium	Premium	Premium	EVP, CBO & Head of Merus US
2022-12-13	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2022-12-01	Premium	acquired	Premium	Premium	Premium	VP Controller, PAO
2022-12-01	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2022-11-03	Premium	bought	Premium	Premium	Premium	President, CEO & PFO
2022-08-25	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2022-08-22	Premium	bought	Premium	Premium	Premium	President, CEO & PFO
2022-08-19	Premium	bought	Premium	Premium	Premium	President, CEO & PFO
2022-07-12	Premium	bought	Premium	Premium	Premium	President, CEO & PFO
2022-06-01	Premium	sold	Premium	Premium	Premium	VP Controller, PAO
2022-06-01	Premium	acquired	Premium	Premium	Premium	VP Controller, PAO
2022-03-10	Premium	sold	Premium	Premium	Premium	EVP, GC and Head of Utrecht
2022-03-10	Premium	acquired	Premium	Premium	Premium	EVP, GC and Head of Utrecht
2021-10-08	Premium	sold	Premium	Premium	Premium	-
2021-10-07	Premium	sold	Premium	Premium	Premium	-
2021-08-12	Premium	sold	Premium	Premium	Premium	SVP & Chief Technology Officer

MRUS - Merus NV Stock Price, Fair Value and News

Latest Insider Trading transactions for MRUS